Can cosentyx alter my body's vaccine immunity?

Can Cosentyx reduce how well vaccines work?

Cosentyx (secukinumab) is an interleukin-17A inhibitor that suppresses parts of the immune system. It treats conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. Because it targets the IL-17 pathway, it may weaken responses to certain vaccines that rely on this branch of immunity.

How do vaccines interact with Cosentyx?

Live vaccines should be avoided while taking Cosentyx. The drug's immune-suppressing effects can increase infection risk from live organisms. Non-live vaccines, such as flu shots or the COVID-19 mRNA vaccines, are generally considered safe, but their effectiveness may be reduced. Studies show lower antibody responses in patients on similar biologic therapies.

When can I get vaccinated after stopping Cosentyx?

Patients should wait at least five half-lives after stopping Cosentyx before receiving live vaccines. Cosentyx has a half-life of approximately 25-30 days, so this time window is roughly 18-25 weeks. Non-live vaccines can be completed before treatment starts or during treatment with antibody testing to assess response.

What vaccines are affected most by Cosentyx?

Influenza, pneumococcal, and tetanus vaccines show reduced antibody titers in patients receiving IL-17 inhibitors. COVID-19 vaccines also have lower seroconversion rates under biologic therapy. Patients often need repeat doses or higher antigen doses to achieve ausreichend immunity.

Can Cosentyx alter established vaccine immunity?

Cosentyx may blunt existing immunity from past vaccinations. It does not erase prior protection outright, but it can lower circulating antibody levels over time. Monitoring antibody titers is recommended for at-risk patients.

Why are companies challenging this patent?

Patent disputes over Cosentyx involve claims that secukinumab is not novel enough to sustain long-term exclusivity. Novartis faces biosimilar challenges in Europe and the US. Some challengers argue that the drug's basic structure is already covered by earlier filings.

When does Cosentyx patent expire?

The main compound patent for secukinumab expires in 2026 in the US. Additional method-of-use and formulation patents push effective exclusivity to 2030 or later. Biosimilars are expected to arrive in 2027 at the earliest.

Can biosimilars enter before patent expiry?

Yes. Biosimilars can launch once core patents expire or through settlement agreements. Novartis has already settled with some potential competitors.